2026 Global: Heart Pump Device Market-Competitive Review (2032) report
Description
The 2026 Global: Heart Pump Device Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Abbott, Medtronic, Edwards Lifesciences, and Terumo dominate the modern heart pump device market, shaping strategies for durable left ventricular assist devices (LVADs) and pulsatile support. Abbott, headquartered in Abbott Park, Illinois, United States, markets the HeartMate 3 LVAD, known for its fully magnetic levitation and reduced thrombosis. Medtronic, based in Dublin, Ireland, has historically deployed LVAD technology through the HVAD platform and continues to expand diversified circulatory support offerings globally. Edwards Lifesciences, headquartered in Irvine, California, United States, emphasizes pulsatile and durable devices with the EXCOR ventricular assist system for pediatric and adult patients, supported by a broad clinical program. Terumo, located in Tokyo, Japan, supplies centrifugal and axial pump technologies, including the DuraHeart LVAD, leveraging its expansive manufacturing and regulatory footprint to support hospitals worldwide. These four companies anchor the high-end segment, while downstream manufacturers and service providers extend adoption through training, service networks, and integration with cardiopulmonary teams.
Abiomed, based in Danvers, Massachusetts, United States, specializes in catheter-friendly, short-term circulatory support with the Impella family as its flagship technology, while maintaining broader training and emergency support programs for hospital systems. SynCardia Systems, headquartered in Tucson, Arizona, United States, operates the Total Artificial Heart and dedicated temporary ventricular assist devices, which remain central to bridging patients to transplant in many centers. LivaNova, headquartered in London, United Kingdom, integrates Sorin's venous-arterial devices and pulsatile arrays into a unified portfolio, supporting pediatric and adult indications through regulatory approvals and manufacturing. Carmat, headquartered in Paris, France, pursues a fully implantable total artificial heart built with biocompatible materials and adaptive control systems, seeking broader access through clinical trials and strategic partnerships. Berlin Heart, based in Berlin, Germany, continues to serve pediatric and select adult patients with its Excor pulsatile LVAD, reinforcing the role of smaller modular devices in advanced heart failure care nationwide.
CardiacAssist, headquartered in Redwood City, California, United States, focuses on short-term circulatory support with percutaneous and surgically implanted devices, including the TandemHeart LVAD, a mainstay for bridging patients to transplant in many centers. The company emphasizes clinician education, device logistics, and integration with cath labs and surgical suites to enable rapid deployment in high-acuity cases. Although market momentum has shifted toward continuous-flow pumps from larger groups, CardiacAssist retains relevance in tertiary care networks where rapid access and procedure-specific customization are essential for timely support. The broader ecosystem in which CardiacAssist operates includes service networks, manufacturer partnerships, and regulatory pathways designed to reduce time-to-support for patients with acute heart failure or cardiogenic shock. When evaluated alongside Abbott, Medtronic, Edwards Lifesciences, Terumo, Abiomed, SynCardia, LivaNova, Carmat, and Berlin Heart, CardiacAssist represents a specialized but persistent niche that complements longer-term devices in centers worldwide. Continued investment in training may broaden its reach globally.
Abbott, Medtronic, Edwards Lifesciences, and Terumo dominate the modern heart pump device market, shaping strategies for durable left ventricular assist devices (LVADs) and pulsatile support. Abbott, headquartered in Abbott Park, Illinois, United States, markets the HeartMate 3 LVAD, known for its fully magnetic levitation and reduced thrombosis. Medtronic, based in Dublin, Ireland, has historically deployed LVAD technology through the HVAD platform and continues to expand diversified circulatory support offerings globally. Edwards Lifesciences, headquartered in Irvine, California, United States, emphasizes pulsatile and durable devices with the EXCOR ventricular assist system for pediatric and adult patients, supported by a broad clinical program. Terumo, located in Tokyo, Japan, supplies centrifugal and axial pump technologies, including the DuraHeart LVAD, leveraging its expansive manufacturing and regulatory footprint to support hospitals worldwide. These four companies anchor the high-end segment, while downstream manufacturers and service providers extend adoption through training, service networks, and integration with cardiopulmonary teams.
Abiomed, based in Danvers, Massachusetts, United States, specializes in catheter-friendly, short-term circulatory support with the Impella family as its flagship technology, while maintaining broader training and emergency support programs for hospital systems. SynCardia Systems, headquartered in Tucson, Arizona, United States, operates the Total Artificial Heart and dedicated temporary ventricular assist devices, which remain central to bridging patients to transplant in many centers. LivaNova, headquartered in London, United Kingdom, integrates Sorin's venous-arterial devices and pulsatile arrays into a unified portfolio, supporting pediatric and adult indications through regulatory approvals and manufacturing. Carmat, headquartered in Paris, France, pursues a fully implantable total artificial heart built with biocompatible materials and adaptive control systems, seeking broader access through clinical trials and strategic partnerships. Berlin Heart, based in Berlin, Germany, continues to serve pediatric and select adult patients with its Excor pulsatile LVAD, reinforcing the role of smaller modular devices in advanced heart failure care nationwide.
CardiacAssist, headquartered in Redwood City, California, United States, focuses on short-term circulatory support with percutaneous and surgically implanted devices, including the TandemHeart LVAD, a mainstay for bridging patients to transplant in many centers. The company emphasizes clinician education, device logistics, and integration with cath labs and surgical suites to enable rapid deployment in high-acuity cases. Although market momentum has shifted toward continuous-flow pumps from larger groups, CardiacAssist retains relevance in tertiary care networks where rapid access and procedure-specific customization are essential for timely support. The broader ecosystem in which CardiacAssist operates includes service networks, manufacturer partnerships, and regulatory pathways designed to reduce time-to-support for patients with acute heart failure or cardiogenic shock. When evaluated alongside Abbott, Medtronic, Edwards Lifesciences, Terumo, Abiomed, SynCardia, LivaNova, Carmat, and Berlin Heart, CardiacAssist represents a specialized but persistent niche that complements longer-term devices in centers worldwide. Continued investment in training may broaden its reach globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
